Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 3/20 | 0.55 |
| ▸ | FABP4 | P15090 | 3/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PRSS12 | P56730 | 5/20 | 0.47 |
| ▸ | ESRRG | P62508 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900100 | 0.89 | HDAC6 (0.55) | FABP3FABP4FABP5NPSR1PRSS12 | |
| SCHEMBL12900103 | 0.84 | FABP3 (0.53) | FABP3FABP4FABP5NPSR1PRSS12 | |
| SCHEMBL7239351 | 0.78 | PRSS12 (0.54) | FABP3FABP4FABP5NPSR1PRSS12 | |
| SCHEMBL18573537 | 0.74 | NPC1 (0.63) | ESRRGTP53SMN1; SMN2 | |
| SCHEMBL14340824 | 0.73 | HCAR2 (0.64) | FABP3FABP4FABP5 | |
| SCHEMBL3091434 | 0.73 | HDAC6 (0.74) | FABP3FABP4PLA2G10 | |
| SCHEMBL12758441 | 0.73 | KMT2A (0.60) | NPSR1PRSS12TP53SMN1; SMN2 | |
| SCHEMBL23813 | 0.72 | HSD17B1 (0.64) | — | |
| SCHEMBL12900106 | 0.72 | HSD17B1 (0.52) | NPSR1PRSS12ESRRGESR1TP53 | |
| SCHEMBL12900081 | 0.72 | STIM1 (0.56) | NPSR1PRSS12ESRRGESR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028462-A1 | Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20110028462-A1 | Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| WO-2007035478-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028462-A1 | Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | FABP3 136/4885FABP4 282/4885FABP5 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.